Celltrion | 068270 - Net Income

Stock Price
169,600.00
Daily Change
-400.00 -0.24%
Monthly
-1.97%
Yearly
-13.38%
Q3 Forecast
167,529.70

Celltrion reported KRW108.67B in Net Income for its fiscal quarter ending in March of 2025.



Financials
Stock Price KRW
Assets KRW 20958.81B
Cash and Equivalent KRW 829.07B
Cost of Sales KRW 399.04B
Current Assets KRW 5461.18B
Current Liabilities KRW 3403.37B
Debt KRW 2217.55B
Dividend Yield 0.42
EBIT KRW 242.47B
EBITDA KRW 221.03B
Employees 1.07K
EPS Earnings Per Share KRW 810.39
Equity Capital and Reserves KRW 17140.89B
Gross Profit on Sales KRW 442.87B
Interest Expense on Debt KRW 17.04B
Interest Income KRW 7.53B
Loan Capital KRW 114.04B
Market Capitalization KRW 36598.01B
Net Income KRW 108.67B
Operating Expenses KRW 718.99B
Operating Profit KRW 242.47B
Ordinary Share Capital KRW 230.8B
PE Price to Earnings KRW 91.32
Pre-Tax Profit KRW 195.49B
Sales Revenues KRW 961.51B
Selling and Administration Expenses KRW 276.8B
Stock KRW 2834.03B
Trade Creditors KRW 106.69B
Trade Debtors KRW 1279.99B

Net Income Change Date
Alaunos Therapeutics USD -742000 385K Dec/2024
Avita Medical AUD -11589000 3.8M Dec/2024
Celltrion KRW 108.67B 127.98B Mar/2025
Dianthus Therapeutics USD -31629000 3.19M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
IQVIA Holdings USD 266M 17M Jun/2025
Moderna USD -825000000 146M Jun/2025
Organon & Co USD 145M 58M Jun/2025
Revvity USD 53.95M 11.71M Jun/2025
Tectonic Therapeutic USD -19980000 7.61M Jun/2025
Viatris USD -4600000 3.04B Jun/2025
Xeris Pharmaceuticals USD -1930000 52.91M Jun/2025